Association of circulating levels of apolipoprotein M and adiponectin with insulin sensitivity in overweight subjects and obese patients with weight loss surgery

Laurent O. Martinez[1], Jean-Bernard Ruidavets[2], Marie Maraninchi[3], Guillaume Combes[1], Jérémy Raffin[4], Philippe de Souto Barreto[2,4], Jean Ferrières[2,5], Bertrand Perret[1], Cédric Moro[1], René Valéro[3], Mikaël Croyal[6,7,8], Nathalie Viguerie[1]

[1] Institut des Maladies Métaboliques et Cardiovasculaires, I2MC, Université de Toulouse, INSERM, Université Toulouse III - Paul Sabatier (UPS), UMR1297, 31432 Toulouse, France

[2] CERPOP UMR 1295, University of Toulouse III, Inserm, UPS, 31000 Toulouse, France

[3] Aix Marseille Université, APHM, INSERM, INRAe, C2VN, Department of Nutrition, Metabolic Diseases and Endocrinology, University Hospital La Conception, 13385 Marseille, France

[4] Gérontopôle de Toulouse, Institut du Vieillissement, Centre Hospitalo-Universitaire de Toulouse, 31000 Toulouse, France

[5] Department of Cardiology, Toulouse Rangueil University Hospital, Toulouse University School of Medicine, Toulouse, France.

[6] Nantes Université, CHU Nantes, CNRS, INSERM, BioCore, US16, SFR Bonamy, 44000 Nantes, France

[7] CRNH-Ouest Mass Spectrometry Core Facility, 44000 Nantes, France

[8] Nantes Université, CHU Nantes, CNRS, INSERM, l'Institut du Thorax, 44000 Nantes, France

Corresponding authors:

Laurent Martinez, INSERM, UMR 1297, 1 Avenue du Pr. Jean Poulhès, BP 84225, 31432 Toulouse, France. Tel: +33561312224147. Email: laurent.martinez@inserm.fr

Nathalie Viguerie, Inserm, UMR 1297, 1 Avenue du Pr. Jean Poulhès, BP 84225, 31432 Toulouse, France. Tel: +33561325631. Email : nathalie.viguerie@inserm.fr

Keywords: adipokine, HOMA-IR, insulin resistance, obesity, metabolic syndrome, diabetes, cardiovascular diseases

Abstract

Background: Most adipokines are up-regulated with obesity and promote metabolic dysfunction, while few, like adiponectin, are down-regulated during adipose tissue expansion and probably protect against obesity-related disorders. High adiponectin is linked to low inflammation and insulin sensitivity. Similarly, apolipoprotein M (apoM) was recently identified as an adipokine for which the expression in adipose tissue is positively associated with metabolic health. Our aim was to compare circulating levels of apoM to those of adiponectin in overweight and obese individuals with respect to metabolic parameters and insulin sensitivity.

Methods: Adiponectin and apoM were measured in a cross-sectional study including 169 overweight men and in a surgery-induced weight loss program including 13 obese patients of both sexes who underwent sleeve gastrectomy. Correlations between the homeostasis model assessment of insulin resistance (HOMA-IR) index, bioclinical parameters, adiponectin and apoM levels, and lifestyle habits were assessed using Spearman correlation coefficients. Multiple regression analyses of HOMA-IR were performed.

Results: In overweight men, plasma adiponectin and apoM were lower in participants with diabetes. The apoM level did not correlate with that of adiponectin and was higher in individuals with dyslipidemia. Similar to adiponectin, apoM was negatively associated with HOMA-IR (r = -0.29), hs-CRP (r = -0.28) and HDL markers (HDL-C, r = 0.32; apoA-I, r = 0.32). Unlike adiponectin, apoM did not correlate with triglyceride levels but was positively associated with LDL markers (LDL-C, r = 0.27; apoB100, r = 0.20) and negatively with fat mass (r = -0.26) and age (r = -0.25). In multiple regression models, apoM was the only negative determinant of HOMA-IR, while adiponectin did not contribute to HOMA-IR variability. Accordingly, while sleeve gastrectomy improved insulin sensitivity, change in HOMA-IR at one year of follow-up was strongly negatively associated with change in the level of circulating apoM (r = -0.71) but not with change in the adiponectin level.

Conclusions: Both circulating apoM and adiponectin are negatively correlated with bioclinical variables associated with obesity, inflammation, and insulin resistance. Unexpectedly, apoM, but not adiponectin, was a negative determinant of HOMA-IR. We identified for the first time circulating apoM as a novel biomarker of insulin sensitivity.

Introduction

Obesity is increasing worldwide [1]. Excessive body fat is associated with metabolic syndrome, and subsequently type 2 diabetes (T2D) and cardiovascular diseases [2].

Adipose tissue (AT) is one of the largest organs in the body. In addition to its role in storing surplus energy, it is also a secretory organ that produces various factors, including numerous adipokines with local and broad systemic effects on whole-body homeostasis [3].

Most adipokines are secreted at higher levels when fat mass increases. They participate in the onset of metabolic disorders associated with obesity, while a small number are inversely associated with body fat content [4]. For example, circulating leptin is directly proportional to body fat mass. It signals on target cells *via* specific receptors and has major roles in the regulation of food intake, fertility, energy expenditure, and atherogenesis [5]. Conversely, adiponectin is an adipose-specific released protein for which the blood concentration decreases with obesity, metabolic syndrome, or T2D [6]. Adiponectin exhibits anti-inflammatory, anti-diabetic, anti-atherogenic, and cardioprotective properties [7].

Recently, the apolipoprotein M (apoM), which is mainly produced by the liver and the kidney, was also described as being released by human AT and produced and secreted by adipocytes [8]. Gene expression of *APOM* in the AT is lower in individuals with high body fat mass, metabolic syndrome, or insulin resistance compared to lean healthy individuals [8]. Accordingly, the blood level of apoM is lowered in obesity, metabolic syndrome, and T2D [9-13]. Overall, apoM is released by adipocytes (adipokine) and exhibits an adipose expression profile in AT and in the circulation similar to that of adiponectin [14]. We therefore hypothesized that adiponectin and apoM could similarly predict changes in insulin sensitivity.

We herein performed a comparative analysis of these two favorable adipokines regarding obesity-related disorders, especially glucose homeostasis. We examined the blood concentrations of both adipokines and investigated their respective association with lipids and glucose homeostasis parameters and contribution to insulin sensitivity.

Methods

Study participants and data collection

Studies (hereafter referred to cohorts A and B) were performed in accordance with the ethical principles of the Declaration of Helsinki. All participants received oral information from the investigators and signed an informed consent form before they participated in any of the study procedures. Figure 1 describes the participants flowchart.

Cohort A: The study protocol was approved by the local ethics committee (CCPPRB, Toulouse/Sud-Ouest, file #1-99-48, Feb 2000). The biological sample collection was declared as DC-2008-463 #1 to the Ministry of Research and to the Regional Health authority. Cohort A was composed of male participants selected from the Genetique et ENvironnement en Europe du Sud (GENES) cross-sectional case-control study designed to investigate the role of genetic, biological, and environmental determinants in the occurrence of coronary artery disease (CAD) [15]. In this ancillary analysis, the participants were CAD patients (further referred to as cases) and age-stratified individuals without CAD (further referred to as controls), in which apoM was simultaneously quantified with Inhibitory factor 1 by multiplex liquid chromatography-tandem mass spectrometry (LC-MS/MS) method [16]. Subjects with missing data for fasting serum insulin and adiponectin levels were excluded, leading to a final sample of 169 participants (mean age 60.6 years [SD, 8.1]) comprising 102 controls and 67 cases. Details regarding the procedures have been reported previously [15]. Briefly, anthropometric, including fat mass assessment using Bioimpedance, and clinical variables were measured. Peripheral venous blood samples were obtained in the morning after an overnight fast for biological analyses. Age, environmental characteristics, and information on medical history and cardiometabolic risk factors were collected through standardized face-to-face interviews performed by a single physician using standardized methods. Alcohol consumption was calculated as the sum of different types of drinks and was expressed as grams per day. For current smokers, cigarette consumption was also recorded as the average number of cigarettes consumed per day. Physical activity was investigated using a standardized questionnaire and categorized into two levels, namely "high", if physical activity was performed for at least 20 min and at least twice a week, or "low", if physical activity was performed for less than 20 min for once a week or less. Dyslipidemia was defined as treatment with drugs or fasting serum total cholesterol ≥ 2.50 g/L. Hypertension was defined as treatment with drugs or systolic blood pressure ≥ 140 mmHg or diastolic blood pressure ≥ 90 mmHg. T2D was defined as treatment with drugs or fasting blood glucose ≥ 7.0 mmol/L.

Cohort B: The study protocol was approved by the Research Ethics Board of Aix-Marseille University (NCT01277068 and NCT02332434). Cohort B involved 13 obese individuals of both sexes (77% women), mean

age 37.6 years [SD, 9.1], undergoing sleeve gastrectomy at the General and Endocrine Surgery Department of La Conception Hospital (Marseille, France), as described previously [17]. The clinical evaluation and laboratory tests were conducted at the Nutrition Department of La Conception Hospital. Patients were examined one month before (baseline) and one year after gastric sleeve surgery to reach steady weight loss. Each visit included measurement of anthropometric parameters and blood sampling after an overnight fast [17].

Biochemical analyses

Fasting blood glucose, triglycerides (TG), cholesterol, high-density lipoprotein-cholesterol (HDL-C), γ-glutamyltransferase (γ-GT), and high-sensitivity C-reactive protein (hs-CRP) were assayed with enzymatic reagents on an automated analyzer (Hitachi 912 and Cobas® Analyzer, Roche Diagnostics). Low-density lipoprotein-cholesterol (LDL-C) was calculated using the Friedewald formula. The blood insulin concentration was measured by electrochemiluminescence immunoassay (Advia Centaur, Siemens Healthineers, cohort A and Cobas® Analyzer, Roche Diagnostics, cohort B). Insulin resistance was assessed using the Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) index calculated as [fasting glucose (mM) x fasting insulin (mU/L)/22.5]. A specific enzyme-linked immunosorbent assay kit was used to measure adiponectin serum levels (Quantikine® Human Adiponectin, R&D Systems). Apolipoprotein A-I (apoA-I), apolipoprotein B100 (apoB100), and apolipoprotein C-III (apoC-III) were determined by immunoturbidimetric assay on an automated analyzer (Cobas® Analyzer, Roche Diagnostics, Cohort A) and by immunonephelometric assay (Roche Diagnostics) using a BN ProSpec analyzer (Siemens Healthineers). ApoM was measured by LC-MS/MS method as described previously [17].

Statistical analyses

The categorical parameters are expressed as numbers (%) and the quantitative parameters as means ± the standard deviation (SD). Shapiro–Wilks test was used to examine the normality of distribution of residuals and Levene's test to determine the homogeneity of the variances. When comparing cases to controls or baseline versus after surgery, the mean values of the quantitative variables were analyzed by Student's *t*-test or Wilcoxon–Mann–Whitney test, depending on the data distribution. When the basic assumptions of Student's *t*-test were not satisfied, the data were logarithmically transformed or subjected to a Wilcoxon–Mann–Whitney test. Associations of apoM, adiponectin, and HOMA-IR with anthropometric parameters, biological markers, and

environmental factors were tested using Spearman's rank correlations. For regression analyses of HOMA-IR, a backward stepwise selection method was used to adjust for confounding variables. The F-statistics for a variable to stay in the model had to be significant at $P < 0.10$. Variables were further maintained in the model when the F-statistic was significant at $P < 0.05$. For each quantitative variable, regression analyses were performed with polynomial models to look for possible nonlinear relationships with dependent variables. Lack of multicollinearity was assessed by examining the variance inflation factors in the final models. Interactions between apoM and coronary status were tested. The specific contribution to the model for each explanatory variable was estimated.

Results

Circulating adiponectin *versus* apoM relationship with cardiometabolic status

The clinical and biological characteristics of cohort A are presented in Supplemental Table 1, for the whole study population and according to individuals' coronary status. Cohort A comprised 169 overweight men (BMI, 26.7 kg/m², [SD, 3.5]), of who 39.6% were CAD patients (cases). Compared with the control participants, the CAD patients had less physical activity and were diagnosed or treated more often for hypertension, dyslipidemia, or diabetes, with a larger proportion suffering from T2D (25.4% versus 6.9% in the controls). The body fat mass percentage and waist circumference were also lower in CAD patients than in the controls. Among the biological markers, the levels of total cholesterol and LDL-C were lower in CAD individuals, probably reflecting the effects of lipid-lowering drugs in patients. However, CAD individuals displayed higher levels of TG, hs-CRP, and γ-GT. HDL markers, HDL-C, and apoA-I were lower. Finally, CAD patients exhibited higher HOMA-IR and lower adiponectin levels than the control participants, while the apoM levels were similar between the two groups. Blood levels of apoM and adiponectin were then considered according to other disease conditions, including diabetes, dyslipidemia, and hypertension (Table 1). Adiponectin and apoM levels were lower in participants diagnosed or treated for T2D (P=0.008 and 0.026, respectively). Unlike adiponectin, apoM levels were significantly lower in participants diagnosed or treated for hypertension (P=0.021), while they were higher in subjects diagnosed or treated for dyslipidemia (P=0.0017) than in the individuals without these conditions. These observations were weakened when only the treatment conditions were considered (Supplemental Table 2), except for adiponectin, for which the levels were lower in participants treated for dyslipidemia (P=0.026) and T2D (P=0.023).

Circulating apoM is a determinant of insulin resistance

Correlations between apoM levels and biological and clinical parameters relative to cardiovascular and diabetes risk factors were investigated in the entire study population and compared with an equivalent correlation for adiponectin and HOMA-IR (Table 2).

The blood level of apoM did not correlate with that of adiponectin. Similar to adiponectin, apoM was negatively associated with hs-CRP (r=-0.28, *P*=0.0001) and HOMA-IR (r=-0.29, *P*=0.0001), while it was positively associated with HDL markers (r=0.32, *P* < 0.0001 for both HDL-C and apoA-I). Unlike adiponectin, apoM did not correlate with TG, but it was positively associated with total cholesterol (r=0.36, *P*<0.0001), LDL markers (LDL-C and apoB100, r=0.27, *P*=0.0004 and r=0.20, *P*=0.007, respectively), and apoC-III (r=0.19, *P*=0.016). Cardiac functions (systolic blood pressure, heart rate) were not associated with apoM or adiponectin, and nor were environmental factors (smoking, physical activity), except for alcohol consumption, which was positively associated with apoM (r=0.19, *P*=0.015). Of note, apoM was also negatively associated with fat mass (r=-0.26, *P*=0.001) and age (r=-0.28*, P*=0.0004).

In addition to be negatively correlated with apoM and adiponectin, HOMA-IR displayed expected negative correlations with HDL markers (apoA-I and HDL-C) and physical activity, and positive correlations with adiposity markers (BMI, fat mass, and waist circumference), TG, apoC-III, hs-CRP, and γ-GT (Table 2).

To further determine which of these HOMA-IR-correlated variables associate with insulin resistance, HOMA-IR was studied as the dependent variable in multiple regression analysis. At entry, the model included apoM and adiponectin as potent explanatory variables together with BMI, waist circumference, physical activity, adiponectin, TG, HDL-C, hs-CRP, γ-GT, apoC-III, apoB100, diabetes, dyslipidemia, hypertension, and case-control status. In this model, which explained 39% of HOMA-IR variability, four variables and diabetes status were found to be determinants of HOMA-IR variability, including apoM but not adiponectin (Table 3). Waist circumference and γ-GT were the strongest determinants of HOMA-IR (13.6% and 9.6%, respectively), being positively related, followed by apoM, which was inversely associated (5.6%). No interaction between apoM and case-control status was found (*P*=0.58). Moreover, when apoM was removed from the set of variables at entry, adiponectin still did not contribute to HOMA-IR variability (data not shown).

Increased circulating apoM is closely related to insulin resistance relief after sleeve gastrectomy

To further study the association between apoM and insulin resistance, we examined the change in circulating apoM after sleeve gastrectomy in obese patients of both sexes and analyzed its association with the improvement in HOMA-IR. Anthropometric and biochemical characteristics of the obese patients at baseline (*i.e.,*

before gastric sleeve surgery) and one year after surgery are presented in Table 4. One year after surgery, all individuals had a decrease in adiposity markers (BMI, fat mass, and waist circumference) and displayed an improved lipid profile, including a decrease in atherogenic lipids (TG and LDL-C) and an increase in HDL markers (HDL-C and apoA-I). A significant decrease in HOMA-IR (4.26, [SD, 1.49] to 1.39, [SD, 0.69], $P<0.001$) and an increase in adiponectin levels (5.54 µg/L, [SD, 1.61] to 10.47 µg/L [SD, 4.07], $P=0.003$) were found, while circulating levels of apoM were unchanged ($P=0.19$) (Table 4). However, there was a strong inverse relationship between changes in HOMA-IR and changes in circulating apoM (r=-0.71, $P=0.01$), while no association was found with changes in adiponectin ($P=0.21$, Figure 1). Of note, there was a trend of positive correlation between changes in circulating apoM and changes in adiponectin (r=0.57, $P=0.08$, not shown).

Discussion

Excessive body fat is associated with numerous cardiometabolic complications such as insulin resistance, T2D and atherosclerosis. Adipose tissue produces and secretes various endocrine factors, called adipokines, into the bloodstream, most of which have increased circulating levels with adipose tissue expansion and are positively associated with obesity-related disorders. Such adipokines are likely to exert detrimental functions on overall metabolism [4]. Conversely, a minority of adipokines, such as adiponectin, exert beneficial systemic actions associated with a decrease in cardiometabolic disorders. Similar to adiponectin, apoM has recently been identified as a novel adipokine for which adipocyte expression and circulating levels were inversely correlated with body fat mass and obesity [8, 11] . ApoM and adiponectin are expressed at lower levels in adipose tissue from patients with metabolic disorders compared with that of healthy individuals, and they have been linked with better glycaemic control [7, 8, 18].

Here, we examined the relationship between the circulating concentrations of these so-called beneficial adipokines, namely adiponectin and apoM, and cardiometabolic parameters, in two high-risk populations composed of overweight men and obese patients who underwent surgical intervention for weight loss. First, the apoM blood level did not correlate with that of adiponectin, suggesting that the levels of these two adipokines are not significantly influenced by each other. Their respective circulating levels, although lower in T2D participants, may reflect some distinct cardiometabolic states. As expected, our study confirmed the previously reported relationships between blood levels of adiponectin and lipids [18-20], with adiponectin being inversely

associated with TG and positively associated with HDL markers (HDL-C and apoA-I). Unlike adiponectin, the circulating apoM level was not associated with plasma TG but was positively correlated with both anti-atherogenic HDL (HDL-C, apoA-I) and atherogenic LDL (LDL-C, apoB100) markers. This association of apoM with both HDL and LDL markers has been reported previously [21-23] and this is likely due to the fact that apoM is transported by both HDL and LDL rather than any specific role of apoM in lipoprotein metabolism [24]. However, apoM is predominantly transported by HDL, and low plasma apoM has been recently reported to be independently associated with heart failure [25], indicating that apoM may contribute to some HDL cardioprotective functions [14].

An expected reduced level of adiponectin was found in CAD patients [20]. In humans, the *ADIPOQ* gene is located on chromosome 3q27, with polymorphisms that influence the level and activity of adiponectin, SNP 276 (G>T) and I164T. The first is associated with obesity, insulin resistance, and T2D [26], while the latter is a missense mutation associated with metabolic syndrome and CAD [27]. An inverse relationship between plasma adiponectin and criteria for metabolic syndrome, low-grade inflammation, T2D, and cardiovascular risk has been repeatedly described [28-30]. However, circulating adiponectin has been paradoxically associated with increased all-cause and cardiovascular mortality [31, 32]. Adiponectin resistance in vessels might be a clue to explain this unexpected outcome on the prognostic value of circulating adiponectin [32, 33].

ApoM was higher in participants with dyslipidemia [13]. This latter observation is consistent with the aforementioned positive association of apoM with LDL-C. Interestingly, the relationship between apoM and the dyslipidemia status was lost when only the treated patients (statin-treated for the majority) were considered among the dyslipidemia subjects, which is consistent with the reported enhancing effect of statins on apoM levels [23]. In addition, apoM levels were lower in subjects with hypertension, which is consistent with its role in reducing blood pressure in hypertensive mice [34].

Similarly to *APOM* expression in AT [8], and consistent with previous reports [18, 25], circulating apoM levels were negatively associated with fat mass and an inflammatory condition, as documented by an elevated hs-CRP level, indicating that a low level of apoM in the blood is a potential marker of systemic inflammation and dysfunctional hypertrophic adipose tissue.

While adiponectin is a recognized key adipokine in preventing metabolic syndrome and consequent pathologies, much less is known regarding apoM, especially regarding its expression by adipocytes. ApoM is distributed in various tissues, being primarily expressed in hepatocytes and proximal tubular kidney cells and to

a lesser extent in endothelial cells and adipocytes [14, 35]. The human *APOM* gene is located on chromosome 6p21.33. There is evidence that T-778C polymorphism in the proximal promoter region of the *APOM* gene confers susceptibility to the development of T2D [36]. Another variant, rs1266078, resulted in an 11% lower circulating apoM level, but no association was found with the risk of T2D [37]. Similar to adiponectin, we found a lower level of apoM in T2D participants and an inverse association with insulin resistance (HOMA-IR). Surprisingly, in a multiple linear regression model, the apoM level in cohort A was the only negative determinant of HOMA-IR, independently of coronary status, while adiponectin did not contribute to HOMA-IR variability. This indicates that in overweight men, plasma apoM is a better determinant of HOMA-IR than circulating adiponectin.

To further explore the link between these two adipokines and insulin resistance, we examined whether weight-reduction surgery in obese patients (cohort B) could influence the levels of apoM and the association with insulin resistance. As reported elsewhere, circulating levels of adiponectin [38] and apoM [39] were lower in obese patients (cohort B, baseline) than in overweight individuals (cohort A), consistent with the above-mentioned negative association of adiponectin and apoM with BMI and fat mass, respectively. Bariatric surgery is an efficient option for the management of obesity, with several procedures available [40]. [41]Among all types of surgery, sleeve gastrectomy is currently the most frequently performed procedure in the world, accounting for 55.4% of all bariatric surgeries [42], and remains the most favorable strategy due to its relative simplicity, minimal invasiveness, and efficiency in terms of weight loss [42, 43]. Sleeve gastrectomy also impairs insulin resistance and improves diabetes [44]. In our study, one year after sleeve gastrectomy, all patients exhibited a HOMA-IR below 2.5 and a two-fold increase in the adiponectin concentration. The minor increase in apoM did not reach significance ($P > 0.1$). However, improvement in insulin sensitivity following weight loss intervention was strongly associated with increased levels of circulating apoM. This reciprocal correlation between apoM and HOMA-IR outcomes suggests that increased levels of circulating apoM could improve glucose homeostasis by reducing insulin resistance. This represents additional evidence that, in addition to adiponectin, apoM may be another beneficial factor of glycaemic control.

Several limitations of this study warrant mention. First, the present study contained 182 subjects and replication studies with a larger sample size are needed to confirm our findings. Second, we did not analyze other molecular isoforms of adiponectin. As there are multiple forms of circulating adiponectin and the high molecular weight isoform is considered the active form [38], further investigations regarding isoform specificity would be

necessary. Finally, studies are needed to assess whether the adipose tissue is a significant production site of apoM and to explore the mechanism by which apoM may prevent insulin resistance.

The present study examined the relative contribution of circulating adiponectin and apoM to metabolic disturbances including whole-body insulin resistance. This study documented for the first time the relative contributions of these adipokines regarding insulin sensitivity. We found that plasma apoM, but not adiponectin, was a negative explanatory variable of HOMA-IR, independently of coronary status. The better relationship of insulin sensitivity with apoM rather than adiponectin was unexpected. This establishes apoM as a new partner in insulin sensitivity.

List of abbreviations

AT: adipose tissue, apoA-I: apolipoprotein A-I; apoB100: apolipoprotein B100; apoC-III: apolipoprotein C-III; apoM: apolipoprotein M; BMI: body mass index; bpm: beats per minute; CAD: coronary artery disease; γ-GT: gamma-glutamyltransferase; HDL-C: high-density lipoprotein cholesterol; HOMA-IR: Homeostasis Model Assessment of Insulin Resistance; hs-CRP: high-sensitivity C-Reactive Protein; LDL-C: low-density lipoprotein cholesterol; T2D: type 2 diabetes.

Declarations

Ethics approval and consent to participate

Studies were performed in accordance with the ethical principles of the Declaration of Helsinki. All participants received oral information from the investigators and signed an informed consent form before they participated in any of the study procedures.

Consent for publication

Not applicable

Availability of data and materials

The datasets analyzed during the current study are not publicly available but are available from the corresponding authors on reasonable request.

Competing interests

The authors have no conflicts of interest to declare.

Funding

This research was funded by the Region Occitanie Pyrénées-Méditerranée (GRAINE HEPATOCARE, Reference number: no. 19014226).

Author contributions

Conceptualization, L.O.M. and N.V.; methodology, LO.M., G.C., J.F., B.P., R.V., M.C., and N.V.; formal analysis, J.B.R. and M.M.; data curation, J.B.R., J.R., and M.C.; writing—original draft preparation, L.O.M. and N.V.; writing—review and editing, L.O.M, J.B.R., M.M., G.C., J.R, P.S.R., J.F.; B.P.; C.M.; R.V.; M.C., and N.V.; supervision, L.O.M. and N.V.; funding acquisition, L.O.M. All authors have read and agreed to the published version of the manuscript. All authors have read and agreed to the published version of the manuscript.

Acknowledgments

We are grateful to all individuals participating in this study.

References

1.   National Academies of Sciences E, and Medicine. In: *Current Status and Response to the Global Obesity Pandemic: Proceedings of a Workshop.* edn. Edited by Callahan EA. Washington (DC); 2019.

2.   Longo M, Zatterale F, Naderi J, Parrillo L, Formisano P, Raciti GA, Beguinot F, Miele C: **Adipose Tissue Dysfunction as Determinant of Obesity-Associated Metabolic Complications**. *International journal of molecular sciences* 2019, **20**(9).

3.   Fasshauer M, Bluher M: **Adipokines in health and disease**. *Trends Pharmacol Sci* 2015, **36**(7):461-470.

4.   Scheja L, Heeren J: **The endocrine function of adipose tissues in health and cardiometabolic disease**. *Nature reviews Endocrinology* 2019, **15**(9):507-524.

5.   Bluher M, Mantzoros CS: **From leptin to other adipokines in health and disease: facts and expectations at the beginning of the 21st century**. *Metabolism: clinical and experimental* 2015, **64**(1):131-145.

6.   Maeda N, Funahashi T, Matsuzawa Y, Shimomura I: **Adiponectin, a unique adipocyte-derived factor beyond hormones**. *Atherosclerosis* 2020, **292**:1-9.

7.   Li X, Zhang D, Vatner DF, Goedeke L, Hirabara SM, Zhang Y, Perry RJ, Shulman GI: **Mechanisms by which adiponectin reverses high fat diet-induced insulin resistance in mice**. *Proceedings of the National Academy of Sciences of the United States of America* 2020, **117**(51):32584-32593.

8.   Sramkova V, Berend S, Siklova M, Caspar-Bauguil S, Carayol J, Bonnel S, Marques M, Decaunes P, Kolditz CI, Dahlman I *et al*: **Apolipoprotein M: a novel adipokine decreasing with obesity and upregulated by calorie restriction**. *The American journal of clinical nutrition* 2019, **109**(6):1499-1510.

9.   Dullaart RP, Plomgaard P, de Vries R, Dahlback B, Nielsen LB: **Plasma apolipoprotein M is reduced in metabolic syndrome but does not predict intima media thickness**. *Clinica chimica acta; international journal of clinical chemistry* 2009, **406**(1-2):129-133.

10.   Kappelle PJ, Lambert G, Dahlback B, Nielsen LB, Dullaart RP: **Relationship of plasma apolipoprotein M with proprotein convertase subtilisin-kexin type 9 levels in non-diabetic subjects**. *Atherosclerosis* 2011, **214**(2):492-494.

11.   Li T, Yang L, Zhao S, Zhang S: **Correlation Between Apolipoprotein M and Inflammatory Factors in Obese Patients**. *Medical science monitor : international medical journal of experimental and clinical research* 2018, **24**:5698-5703.

12.   Plomgaard P, Dullaart RP, de Vries R, Groen AK, Dahlback B, Nielsen LB: **Apolipoprotein M predicts pre-beta-HDL formation: studies in type 2 diabetic and nondiabetic subjects**. *Journal of internal medicine* 2009, **266**(3):258-267.

13.   Zhang P, Gao J, Pu C, Feng G, Wang L, Huang L, Tao Q, Zhang Y: **Effects of hyperlipidaemia on plasma apolipoprotein M levels in patients with type 2 diabetes mellitus: an independent case-control study**. *Lipids in health and disease* 2016, **15**(1):158.

14.   Tavernier G, Caspar-Bauguil S, Viguerie N: **Apolipoprotein M: new connections with diet, adipose tissue and metabolic syndrome**. *Current opinion in lipidology* 2020, **31**(1):8-14.

15.   Genoux A, Ruidavets JB, Ferrieres J, Combes G, Lichtenstein L, Pons V, Laffargue M, Taraszkiewicz D, Carrie D, Elbaz M *et al*: **Serum IF1 concentration is independently associated to HDL levels and to coronary heart disease: the GENES study**. *Journal of lipid research* 2013, **54**(9):2550-2558.

16.   Genoux A, Duparc T, Ruidavets JB, Ingueneau C, Najib S, Ferrieres J, Perret B, Croyal M, Martinez LO: **A reference measurement of circulating ATPase inhibitory factor 1 (IF1) in humans by LC-MS/MS: Comparison with conventional ELISA**. *Talanta* 2020, **219**:121300.

17.   Poirier J, Cloteau C, Aguesse A, Billot X, Thevenot E, Krempf M, Valero R, Maraninchi M, Croyal M: **Bariatric Surgery Improves the Atherogenic Profile of Circulating Methylarginines in Obese Patients: Results from a Pilot Study**. *Metabolites* 2021, **11**(11).

18.   Schulze MB, Rimm EB, Shai I, Rifai N, Hu FB: **Relationship between adiponectin and glycemic control, blood lipids, and inflammatory markers in men with type 2 diabetes**. *Diabetes care* 2004, **27**(7):1680-1687.

19.   Baratta R, Amato S, Degano C, Farina MG, Patane G, Vigneri R, Frittitta L: **Adiponectin relationship with lipid metabolism is independent of body fat mass: evidence from both cross-sectional and intervention studies**. *The Journal of clinical endocrinology and metabolism* 2004, **89**(6):2665-2671.

20.   Hascoet S, Elbaz M, Bongard V, Bouisset F, Verdier C, Vindis C, Genoux A, Taraszkiewicz D, Perret B, Galinier M *et al*: **Adiponectin and long-term mortality in coronary artery disease participants and controls**. *Arteriosclerosis, thrombosis, and vascular biology* 2013, **33**(1):e19-29.

21.   Christoffersen C, Benn M, Christensen PM, Gordts P, Roebroek AJM, Frikke-Schmidt R, Tybjaerg-Hansen A, Dahlback B, Nielsen LB: **The plasma concentration of HDL-associated**

apoM is influenced by LDL receptor-mediated clearance of apoB-containing particles. *Journal of lipid research* 2012, **53**(10):2198-2204.

22. Dahlback B, Nielsen LB: **Apolipoprotein M affecting lipid metabolism or just catching a ride with lipoproteins in the circulation?** *Cellular and molecular life sciences : CMLS* 2009, **66**(4):559-564.

23. Kappelle PJ, Ahnstrom J, Dikkeschei BD, de Vries R, Sluiter WJ, Wolffenbuttel BH, van Tol A, Nielsen LB, Dahlback B, Dullaart RP: **Plasma apolipoprotein M responses to statin and fibrate administration in type 2 diabetes mellitus**. *Atherosclerosis* 2010, **213**(1):247-250.

24. Borup A, Christensen PM, Nielsen LB, Christoffersen C: **Apolipoprotein M in lipid metabolism and cardiometabolic diseases**. *Current opinion in lipidology* 2015, **26**(1):48-55.

25. Chirinos JA, Zhao L, Jia Y, Frej C, Adamo L, Mann D, Shewale SV, Millar JS, Rader DJ, French B *et al*: **Reduced Apolipoprotein M and Adverse Outcomes Across the Spectrum of Human Heart Failure**. *Circulation* 2020, **141**(18):1463-1476.

26. Vasseur F, Helbecque N, Dina C, Lobbens S, Delannoy V, Gaget S, Boutin P, Vaxillaire M, Lepretre F, Dupont S *et al*: **Single-nucleotide polymorphism haplotypes in the both proximal promoter and exon 3 of the APM1 gene modulate adipocyte-secreted adiponectin hormone levels and contribute to the genetic risk for type 2 diabetes in French Caucasians**. *Hum Mol Genet* 2002, **11**(21):2607-2614.

27. Ohashi K, Ouchi N, Kihara S, Funahashi T, Nakamura T, Sumitsuji S, Kawamoto T, Matsumoto S, Nagaretani H, Kumada M *et al*: **Adiponectin I164T mutation is associated with the metabolic syndrome and coronary artery disease**. *Journal of the American College of Cardiology* 2004, **43**(7):1195-1200.

28. Duncan BB, Schmidt MI, Pankow JS, Bang H, Couper D, Ballantyne CM, Hoogeveen RC, Heiss G: **Adiponectin and the development of type 2 diabetes: the atherosclerosis risk in communities study**. *Diabetes* 2004, **53**(9):2473-2478.

29.   Mojiminiyi OA, Abdella NA, Al Arouj M, Ben Nakhi A: **Adiponectin, insulin resistance and clinical expression of the metabolic syndrome in patients with Type 2 diabetes**. *Int J Obes (Lond)* 2007, **31**(2):213-220.

30.   Okamoto Y, Kihara S, Funahashi T, Matsuzawa Y, Libby P: **Adiponectin: a key adipocytokine in metabolic syndrome**. *Clin Sci (Lond)* 2006, **110**(3):267-278.

31.   Beatty AL, Zhang MH, Ku IA, Na B, Schiller NB, Whooley MA: **Adiponectin is associated with increased mortality and heart failure in patients with stable ischemic heart disease: data from the Heart and Soul Study**. *Atherosclerosis* 2012, **220**(2):587-592.

32.   Wang Y, Ma XL, Lau WB: **Cardiovascular Adiponectin Resistance: The Critical Role of Adiponectin Receptor Modification**. *Trends in endocrinology and metabolism: TEM* 2017, **28**(7):519-530.

33.   Van Berendoncks AM, Garnier A, Beckers P, Hoymans VY, Possemiers N, Fortin D, Martinet W, Van Hoof V, Vrints CJ, Ventura-Clapier R *et al*: **Functional adiponectin resistance at the level of the skeletal muscle in mild to moderate chronic heart failure**. *Circ Heart Fail* 2010, **3**(2):185-194.

34.   Swendeman SL, Xiong Y, Cantalupo A, Yuan H, Burg N, Hisano Y, Cartier A, Liu CH, Engelbrecht E, Blaho V *et al*: **An engineered S1P chaperone attenuates hypertension and ischemic injury**. *Science signaling* 2017, **10**(492).

35.   Bisgaard LS, Christoffersen C: **Apolipoprotein M/sphingosine-1-phosphate: novel effects on lipids, inflammation and kidney biology**. *Current opinion in lipidology* 2019, **30**(3):212-217.

36.   Niu N, Zhu X, Liu Y, Du T, Wang X, Chen D, Sun B, Gu HF: **Single nucleotide polymorphisms in the proximal promoter region of apolipoprotein M gene (apoM) confer the susceptibility to development of type 2 diabetes in Han Chinese**. *Diabetes/metabolism research and reviews* 2007, **23**(1):21-25.

37.   Liu D, Pan JM, Pei X, Li JS: **Interaction Between Apolipoprotein M Gene Single-Nucleotide Polymorphisms and Obesity and its Effect on Type 2 Diabetes Mellitus Susceptibility**. *Scientific reports* 2020, **10**(1):7859.

38.   Wang ZV, Scherer PE: **Adiponectin, the past two decades**. *Journal of molecular cell biology* 2016, **8**(2):93-100.

39.   Ooi EM, Watts GF, Chan DC, Nielsen LB, Plomgaard P, Dahlback B, Barrett PH: **Association of apolipoprotein M with high-density lipoprotein kinetics in overweight-obese men**. *Atherosclerosis* 2010, **210**(1):326-330.

40.   Breen DM, Rasmussen BA, Kokorovic A, Wang R, Cheung GW, Lam TK: **Jejunal nutrient sensing is required for duodenal-jejunal bypass surgery to rapidly lower glucose concentrations in uncontrolled diabetes**. *Nature medicine* 2012, **18**(6):950-955.

41.   Ionut V, Burch M, Youdim A, Bergman RN: **Gastrointestinal hormones and bariatric surgery-induced weight loss**. *Obesity (Silver Spring)* 2013, **21**(6):1093-1103.

42.   Angrisani L, Santonicola A, Iovino P, Ramos A, Shikora S, Kow L: **Bariatric Surgery Survey 2018: Similarities and Disparities Among the 5 IFSO Chapters**. *Obes Surg* 2021, **31**(5):1937-1948.

43.   Buchwald H, Oien DM: **Metabolic/bariatric surgery worldwide 2011**. *Obes Surg* 2013, **23**(4):427-436.

44.   Salman AA, Salman MA, Marie MA, Rabiee A, Helmy MY, Tourky MS, Qassem MG, Shaaban HE, Sarhan MD: **Factors associated with resolution of type-2 diabetes mellitus after sleeve gastrectomy in obese adults**. *Scientific reports* 2021, **11**(1):6002.

Tables

Table 1. Adiponectin and apoM levels in cohort A according to cardiometabolic status

		n	ApoM (mg/L)	*P*-value	Adiponectin (μg/mL)[a]	*P*-value
Diabetes[b]						
	no	145	26.3 (7.1)	**0.026**	7.6 (5.3)	**0.008**
	yes	24	22.8 (7.1)		4.9 (3.4)	
Dyslipidemia[c]						
	no	76	23.9 (6.2)	**0.0017**	7.8 (4.9)	0.21
	yes	93	27.3 (7.5)		6.7 (5.4)	
Hypertension[d]						
	no	82	27.1 (6.7)	**0.021**	7.7 (4.6)	0.26
	yes	87	24.5 (7.3)		6.8 (5.6)	

ApoM and adiponectin were measured at baseline (i.e. when individuals were first included in the GENES cohort) and expressed as means (SD).

Student's t-test; *P*-values < 0.05 are indicated in bold.

[a]Log-transformed data.

[b]Diabetes, fasting blood glucose ≥7.0 mmol/L or treatment.

[c]Dyslipidemia, total cholesterol ≥2.50 g/L or treatment.

[d]Hypertension, systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg or treatment.

Table 2. Spearman correlation coefficients of adiponectin, apoM and HOMA-IR with anthropometric parameters, biological markers and environmental factors in cohort A

	Adiponectin (μg/mL)	ApoM (mg/L)	HOMA-IR
Adiponectin	1		**-0.19** (-0.33;-0.04)*
ApoM	-0.01 (-0.17;0.14)	1	**-0.29** (-0.42;-0.14)***
HOMA-IR			1
Insulin	**-0,17** (-0.32;-0.02)*	**-0.31** (-0.44;-0.161)***	_
Glucose	-0.06 (-0.21;0.09)	-0.085 (-0.234;0.068)	_
BMI	**-0.21** (-0.35;-0.06)**	-0.05 (-0.20;0.10)	**0.43** (0.30;0.55)***
Waist circumference	**-0.25** (-0.38;-0.10)**	-0.11 (-0.29;0.04)	**0.49** (0.36;0.60)***
Fat mass percent	-0.09 (-0.25;0.07)	**-0.26** (-0.40;-0.10)**	**0.42** (0.28;0.54)***
Triglycerides	**-0.30** (-0.43;-0.15)***	-0.01 (-0.16;0.15)	**0,41** (0.28;0.53)***
Total cholesterol	0.13 (-0.03;0.27)	**0.36** (0.22;0.48)***	-0.05 (-0.20;0.10)
LDL-C	0.09 (0.07;0.23)	**0.27** (0.12;0.40)***	-0.05 (-0.20;0.10)
HDL-C	**0.41** (0.27;0.53)***	**0.32** (0.18;0.45)***	**-0.34** (-0.47;-0.20)***
ApoA-I	**0.34** (0.19;0.46)***	**0.32** (0.17;0.45)***	**-0.26** (-0.40;-0.11)***
ApoB100	-0.06 (-0.21;0.09)	**0.20** (0.04;0.34)***	0.14 (-0.01;0.29)
ApoC-III	0.06 (-0.03;0.21)	**0.19** (0.04;0.34)*	**0.28** (0.13;0.41)***
hs-CRP	**-0.22** (-0.36;-0.07)**	**-0,28** (-0.42;-0.13)***	**0,30** (0,15;0,43)***
γ-GT	-0.14 (-0.29;0.01)	-0.04 (-0.19;0.11)	0.41 (0.27;0.53)***
Age	0.09 (-0.06;0.24)	**-0.28** (-0.38;-0.11)***	0.08 (-0.07;0.23)
Alcohol	-0.01 (-0.16;0.14)	**0.19** (0.04;0.34)*	-0.03 (-0.18;0.12)
Smoking	0.04 (-0.11;0.19)	0.02 (-0.13;0.17)	0.05 (-0.11;0.20)
Physical activity	0.05 (-0.10;0.20)	0.01 (-0.15;0.16)	**-0.26** (-0.39;-0.11)***
Systolic blood pressure	-0.03 (-0.18;0.13)	-0.12 (-0.27;0.03)	0.07 (-0.08;0.22)
Diastolic blood pressure	-0.03 (-0.18;0.12)	0.03 (-0.12;0.19)	0.07 (-0.08;0.22)
Resting heart rate	0.11 (-0.06;0.25)	-0.15 (-0.29;0.01)	**0.23** (0.08;0.37)**

Spearman rank correlation (95% confidence interval), n=169.

*$P<0.05$, ** $P <0.01$, *** $P <0.001$. P-values < 0.05 are indicated in bold.
ApoA-I: apolipoprotein A-I; ApoB-100: apolipoprotein B100; ApoC-III: apolipoprotein C-III; BMI, body mass index; hs-CRP, high-sensitivity C-reactive protein; γ-GT, gamma glutamyl transferase; HDL-C, high-density lipoprotein-cholesterol; HOMA-IR: Homeostasis Model Assessment of Insulin Resistance; LDL-C, low-density lipoprotein-cholesterol.

Table 3. Multiple linear regression analysis on HOMA-IR in cohort A

	β estimate	SE	*P*-value	%[b]
	R^2=39			
ApoM	-0.133	0.045	0.0035	5.6
Waist circumference[a]	0.177	0.046	0.0002	13.6
γ-GT[a]	0.181	0.046	0.0001	9.6
ApoC-III[a]	1.421	0.044	0.0016	4.5
Diabetes	0.353	0.132	0.0084	2.8

Variables at entry: Adiponectin, apoC-III, apoB-100, apoM, BMI, γ-GT, hs-CRP, HDL-C, physical activity, triglycerides, waist circumference, diabetes (fasting blood glucose ≥7.0 mmol/L or treatment *vs*. no), dyslipidemia (total cholesterol ≥2.50 g/L or treatment), hypertension (systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg or treatment) and case-control status. Continuous variables were standardised. β estimates were given for one standard deviation variation.

[a]Log-transformed data; [b]Percentage of variance explained.

ApoB-100: apolipoprotein B100; ApoC-III: apolipoprotein C-III; ApoM: apolipoprotein M; BMI: body mass index; γ-GT: gamma-glutamyltransferase; HDL-C: high-density lipoprotein cholesterol; hs-CRP: high-sensitivity C-Reactive Protein; HOMA-IR, Homeostasis Model Assessment of Insulin Resistance; LDL-C: low-density lipoprotein cholesterol.

Table 4. Anthropometric, biological and clinical characteristics at baseline and one year after sleeve gastrectomy in cohort B.

	Baseline	n	One-year after sleeve gastrectomy	n	*P*-value
BMI, kg/m^2	42.2 (4.6)	13	28.5 (3.9)	13	**<0.001**
Fat mass,% body weight	49.8 (5.3)	13	35.4 (5.6)	13	**<0.001**
Fasting glucose, mmol/L	5.4 (0.7)	13	4.6 (0.4)	13	**0.044**
Insulin, IU/L	18.3 (7.1)	13	6.9 (3.6)	11	**<0.001**
HOMA-IR	4.3 (1.5)	13	1.4 (0.7)	11	**<0.001**
Adiponectin, μg/L	5.2 (1.6)	13	10.5 (4.1)	11	**0.003**
ApoM, mg/L	6.8 (2.7)	13	7.7 (2.7)	13	0.190
Triglycerides, g/L	1.22 (0.52)	13	0.70 (0.20)	13	**0.003**
Total cholesterol, g/L	1.88 (0.28)	13	1.81 (0.24)	13	**0.077**
LDL-C, g/L	1.22 (0.21)	13	1.09 (0.21)	13	**0.032**
HDL-C, g/L	0.41 (0.09)	13	0.56 (0.08)	13	**0.002**
ApoA-I, g/L	1.43 (0.17)	13	1.58 (0.19)	13	**0.002**
ApoB-100, g/L	0.93 (0.17)	13	0.84 (0.14)	13	**0.029**
ApoC-III, mg/L	82.7 (41.9)	13	74.1 (19.5)	13	0.117
hs-CRP, mg/L	10.1 (8.0)	13	2.3 (2.0)	13	**0.004**
γ-GT, IU/L	34.6 (32.6)	13	16.5 (14.2)	12	**0.017**
Systolic blood pressure, mm Hg	115 (7)	13	117 (14)	13	0.202
Diastolic blood pressure, mm Hg	68 ± 14	13	73 ± 13	13	0.362

Data are expressed as means (SD).

Wilcoxon signed ranks test; *P*-values < 0.05 are indicated in bold.

ApoA-I: apolipoprotein A-I; ApoB-100: apolipoprotein B100; ApoC-III: apolipoprotein C-III; BMI, body mass index; hs-CRP, high-sensitivity C-reactive protein; γ-GT, gamma glutamyl transferase; HDL-C, high-density lipoprotein-cholesterol; HOMA-IR: Homeostasis Model Assessment of Insulin Resistance; LDL-C, low-density lipoprotein-cholesterol.

Figure legends

Figure 1. Flowchart of participants. CAD: coronary artery disease; HOMA-IR: Homeostasis Model Assessment of Insulin Resistance; HT: Hypertension; SG: sleeve gastrectomy; T2D: type2 diabetes.

Figure 2. Changes in circulating apoM and adiponectin relationship with improvement of insulin sensitivity after bariatric surgery. Sera from 11 obese individuals (cohort B) were tested for apoM (panel A) and adiponectin (panel B) levels before and one year after sleeve gastrectomy. Changes in adipokine concentrations were correlated to the changes in the Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) index. Linear correlation coefficients and *P*-values are displayed in each graph. The dotted lines represent 95% confidence intervals.